DEBATE: The Evidence Supporting The Value Of Peri-Operative Beta Blockers In Lowering Morbidity Of Vascular Procedures Is Weak And They May Be Harmful: What Should We Do: Is It Just A Dosage Problem

The Best Antiplatelet And Anticoagulant Medications For Patients With Aggressive PAD: How Important Are LDL-C Levels: When Should Ezetemibe (Zetia) And PCSK-9 Inhibitors Be Added To Statins

How Can Vascular Surgeon-Scientists Survive In Today’s Unfriendly DRG/RVU Climate

Experimental Insights In Acute DVT And Post-Thrombotic Syndrome

Non-Fasting Lipid Profiles Are A Simplification With No Negative Consequences For Diagnosis, Risk Evaluation And Treatment